Danish Stock News

As European markets face a pullback amid concerns over artificial intelligence stock valuations, major indices like the STOXX Europe 600 and Germany's DAX have seen declines. In this environment of cautious sentiment, identifying undervalued stocks can provide opportunities for investors seeking potential value plays.

Most people feel a little frustrated if a stock they own goes down in price. But sometimes broader market conditions...

TORM (CPSE:TRMD A) shares have delivered a 25% gain over the past 3 months, catching the attention of investors interested in the energy sector. The stock’s performance makes it a common conversation starter for those tracking Nordic shipping companies. See our latest analysis for TORM. TORM’s recent 24.7% share price return over the last 90 days stands out against an otherwise steady year, suggesting that momentum may be building again after a relatively muted period. While the 12-month...

It's been a mediocre week for GN Store Nord A/S ( CPH:GN ) shareholders, with the stock dropping 10% to kr.102 in the...

Shareholders might have noticed that Solar A/S ( CPH:SOLAR B ) filed its quarterly result this time last week. The...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its latest third-quarter results and things are looking bullish...

Key Insights Given the large stake in the stock by institutions, DSV's stock price might be vulnerable to their trading...

Coloplast (CPSE:COLO B) is projecting healthy momentum, with earnings forecast to grow at 15.8% per year, outpacing the Danish market's 3.7% average. Revenue is also expected to climb at 6.9% annually, ahead of the market's 5% rate. Despite these positive forecasts, the company’s net profit margin has contracted to 13% from 18.7% last year. Five-year earnings growth has averaged just 0.03% per year, with earnings declining over the past year. Investors are eyeing Coloplast’s above-market...

Wondering if Bavarian Nordic is a hidden gem or simply riding the latest biotech wave? Let's dig in and see if the stock is living up to its reputation. Bavarian Nordic shares have seen a solid 18.2% jump year-to-date and are up 13.6% over the past year, but there was a slight dip of 0.6% just last week. Recent headlines highlight the company's expanding role in vaccine development, with positive investor sentiment driven by new partnerships and regulatory milestones. These developments have...

Curious if Novozymes is worth a closer look, whether you are already holding shares or just valuation-savvy? Let’s get straight to what matters for investors weighing the company’s true worth. The share price has slipped by 2.5% over the past week and is down 9.2% in the past year, hinting at shifting sentiment and fresh questions around growth potential. Recent headlines around Novozymes' strategic initiatives in sustainable bio-solutions and its ongoing integration efforts with Chr. Hansen...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Thinking about whether FLSmidth stock is a bargain, or perhaps getting a bit pricey? Let’s take a closer look at what’s really going on beneath the surface. Over the last year, FLSmidth’s share price has surged 39.4%, and it’s up a remarkable 34.5% year-to-date, even after a recent dip of 5.2% in the last week. One driver for these moves has been ongoing sector consolidation news and recent project wins, fueling optimism around future growth and improved margins. In the same period, market...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...

Wondering if Danske Bank is a hidden gem or already priced to perfection? Let's dig into what the numbers and recent market action are signaling about its current value. Danske Bank’s stock has been on a tear, surging 6.3% in the past week and up 42.0% year-to-date, with an impressive 52.7% gain over the last 12 months. Recent news highlights Danske Bank’s ongoing digital transformation and several strategic partnerships, both of which have caught investor attention. Industry talk about...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

The Netcompany Group A/S ( CPH:NETC ) share price has done very well over the last month, posting an excellent gain of...

With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...

Despite an already strong run, GreenMobility A/S ( CPH:GREENM ) shares have been powering on, with a gain of 25% in the...

There wouldn't be many who think Carlsberg A/S' ( CPH:CARL B ) price-to-earnings (or "P/E") ratio of 15.4x is worth a...

Per Aarsleff Holding (CPH:PAAL B) has had a great run on the share market with its stock up by a significant 14% over...

Key Insights The projected fair value for TORM is kr.225 based on 2 Stage Free Cash Flow to Equity TORM's kr.139 share...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Embla Medical hf (CPSE:EMBLA) posted earnings forecast to grow at 14.51% per year, with revenue set to rise by 8.5% annually. Both figures are ahead of the Danish market’s expected growth. The company’s net profit margin edged up to 8.6% from 8.2% the year before. While the most recent year’s earnings growth came in at 11.7%, the broader five-year average sits at a robust 19.2% per year. Embla’s combination of faster-than-market growth and steadily improving profitability, coupled with a lack...